BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Khalil F, Läer S. Physiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug development. J Biomed Biotechnol. 2011;2011:907461. [PMID: 21716673 DOI: 10.1155/2011/907461] [Cited by in Crossref: 61] [Cited by in F6Publishing: 46] [Article Influence: 6.1] [Reference Citation Analysis]
Number Citing Articles
1 McDaniel M, Carter J, Keller J, White S, Baird A. Open Source PKPD Frame Work: Tutorial on the BioGears Engine. CPT Pharmacometrics Syst Pharmacol 2018. [PMID: 30411537 DOI: 10.1002/psp4.12371] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
2 Rasool MF, Khalil F, Läer S. A physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flows. Clin Pharmacokinet 2015;54:943-62. [PMID: 25773479 DOI: 10.1007/s40262-015-0253-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 5.6] [Reference Citation Analysis]
3 Rioux N, Waters NJ. Physiologically Based Pharmacokinetic Modeling in Pediatric Oncology Drug Development. Drug Metabolism and Disposition 2016;44:934-43. [DOI: 10.1124/dmd.115.068031] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
4 Thai HT, Mazuir F, Cartot-Cotton S, Veyrat-Follet C. Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel. Br J Clin Pharmacol 2015;80:534-47. [PMID: 26095234 DOI: 10.1111/bcp.12702] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
5 Duan P, Fisher JW, Wang J. Applications of Physiologically Based Pharmacokinetic (PBPK) Models for Pediatric Populations. In: Mahmood I, Burckart G, editors. Fundamentals of Pediatric Drug Dosing. Cham: Springer International Publishing; 2016. pp. 109-25. [DOI: 10.1007/978-3-319-43754-5_8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
6 van Hasselt JG, van Eijkelenburg NK, Beijnen JH, Schellens JH, Huitema AD. Optimizing drug development of anti-cancer drugs in children using modelling and simulation. Br J Clin Pharmacol 2013;76:30-47. [PMID: 23216601 DOI: 10.1111/bcp.12062] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
7 Surve DH, Jindal AB. Recent advances in long-acting nanoformulations for delivery of antiretroviral drugs. J Control Release 2020;324:379-404. [PMID: 32461114 DOI: 10.1016/j.jconrel.2020.05.022] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 15.0] [Reference Citation Analysis]
8 Wadsworth I, Hampson LV, Jaki T. Extrapolation of efficacy and other data to support the development of new medicines for children: A systematic review of methods. Stat Methods Med Res 2018;27:398-413. [PMID: 26994211 DOI: 10.1177/0962280216631359] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
9 Kulo A, van Calsteren K, Verbesselt R, Smits A, Devlieger R, de Hoon J, Allegaert K. The impact of Caesarean delivery on paracetamol and ketorolac pharmacokinetics: a paired analysis. J Biomed Biotechnol. 2012;2012:437639. [PMID: 22675252 DOI: 10.1155/2012/437639] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
10 Allegaert K. Clinical pharmacological studies in children: From exploratory towards confirmation driven methodology. World J Clin Pediatr. 2012;1:3-7. [PMID: 25254160 DOI: 10.5409/wjcp.v1.i2.3] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
11 Díaz de León-Ortega R, D'Arcy DM, Lamprou DA, Fotaki N. In vitro - in vivo relations for the parenteral liposomal formulation of Amphotericin B: A clinically relevant approach with PBPK modeling. Eur J Pharm Biopharm 2020;:177-87. [PMID: 32147578 DOI: 10.1016/j.ejpb.2020.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Hu ZY, Lu J, Zhao Y. A physiologically based pharmacokinetic model of alvespimycin in mice and extrapolation to rats and humans. Br J Pharmacol 2014;171:2778-89. [PMID: 24471734 DOI: 10.1111/bph.12609] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
13 Ferguson BS, Hoggarth DA, Maliniak D, Ploense K, White RJ, Woodward N, Hsieh K, Bonham AJ, Eisenstein M, Kippin TE, Plaxco KW, Soh HT. Real-time, aptamer-based tracking of circulating therapeutic agents in living animals. Sci Transl Med 2013;5:213ra165. [PMID: 24285484 DOI: 10.1126/scitranslmed.3007095] [Cited by in Crossref: 186] [Cited by in F6Publishing: 144] [Article Influence: 26.6] [Reference Citation Analysis]
14 Lu X, Bi K, Chen X. Physiologically based pharmacokinetic model of docetaxel and interspecies scaling: comparison of simple injection with folate receptor-targeting amphiphilic copolymer-modified liposomes. Xenobiotica 2016;46:1093-104. [DOI: 10.3109/00498254.2016.1155128] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
15 Khalil F, Läer S. Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range-sotalol as a model drug. AAPS J 2014;16:226-39. [PMID: 24399240 DOI: 10.1208/s12248-013-9555-6] [Cited by in Crossref: 50] [Cited by in F6Publishing: 37] [Article Influence: 7.1] [Reference Citation Analysis]
16 Utembe W, Clewell H, Sanabria N, Doganis P, Gulumian M. Current Approaches and Techniques in Physiologically Based Pharmacokinetic (PBPK) Modelling of Nanomaterials. Nanomaterials (Basel) 2020;10:E1267. [PMID: 32610468 DOI: 10.3390/nano10071267] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
17 Griffin BT, Guo J, Presas E, Donovan MD, Alonso MJ, O'driscoll CM. Pharmacokinetic, pharmacodynamic and biodistribution following oral administration of nanocarriers containing peptide and protein drugs. Advanced Drug Delivery Reviews 2016;106:367-80. [DOI: 10.1016/j.addr.2016.06.006] [Cited by in Crossref: 57] [Cited by in F6Publishing: 42] [Article Influence: 11.4] [Reference Citation Analysis]
18 Läer S, Meibohm B. Study design and simulation approach. Handb Exp Pharmacol 2011;205:125-48. [PMID: 21882109 DOI: 10.1007/978-3-642-20195-0_6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
19 Mattison DR, Karyakina N, Goodman M, Lakind JS. Pharmaco- and toxicokinetics of selected exogenous and endogenous estrogens: A review of the data and identification of knowledge gaps. Critical Reviews in Toxicology 2014;44:696-724. [DOI: 10.3109/10408444.2014.930813] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 5.9] [Reference Citation Analysis]
20 Batchelor HK, Kendall R, Desset-Brethes S, Alex R, Ernest TB; European Paediatric Formulation Initiative. Application of in vitro biopharmaceutical methods in development of immediate release oral dosage forms intended for paediatric patients. Eur J Pharm Biopharm 2013;85:833-42. [PMID: 23665448 DOI: 10.1016/j.ejpb.2013.04.015] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
21 Rashid M, Sarfraz M, Arafat M, Hussain A, Abbas N, Sadiq MW, Rasool MF, Bukhari NI. Prediction of lisinopril pediatric dose from the reference adult dose by employing a physiologically based pharmacokinetic model. BMC Pharmacol Toxicol 2020;21:56. [PMID: 32727574 DOI: 10.1186/s40360-020-00429-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
22 Allegaert K, Smits A, van den Anker JN. Physiologically based pharmacokinetic modeling in pediatric drug development: a clinician's request for a more integrated approach. J Biomed Biotechnol. 2012;2012:103763. [PMID: 22500073 DOI: 10.1155/2012/103763] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
23 Hartmanshenn C, Scherholz M, Androulakis IP. Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine. J Pharmacokinet Pharmacodyn 2016;43:481-504. [PMID: 27647273 DOI: 10.1007/s10928-016-9492-y] [Cited by in Crossref: 50] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
24 Sassen SDT, Zwaan CM, van der Sluis IM, Mathôt RAA. Pharmacokinetics and population pharmacokinetics in pediatric oncology. Pediatr Blood Cancer 2020;67:e28132. [PMID: 31876123 DOI: 10.1002/pbc.28132] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Yellepeddi V, Rower J, Liu X, Kumar S, Rashid J, Sherwin CMT. State-of-the-Art Review on Physiologically Based Pharmacokinetic Modeling in Pediatric Drug Development. Clin Pharmacokinet 2019;58:1-13. [PMID: 29777528 DOI: 10.1007/s40262-018-0677-y] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 27.0] [Reference Citation Analysis]
26 Wu Q, Peters SA. A Retrospective Evaluation of Allometry, Population Pharmacokinetics, and Physiologically-Based Pharmacokinetics for Pediatric Dosing Using Clearance as a Surrogate. CPT Pharmacometrics Syst Pharmacol 2019;8:220-9. [PMID: 30762304 DOI: 10.1002/psp4.12385] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
27 Min JS, Bae SK. Prediction of drug–drug interaction potential using physiologically based pharmacokinetic modeling. Arch Pharm Res 2017;40:1356-79. [DOI: 10.1007/s12272-017-0976-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 6.8] [Reference Citation Analysis]
28 Smits A, Annaert P, Van Cruchten S, Allegaert K. A Physiology-Based Pharmacokinetic Framework to Support Drug Development and Dose Precision During Therapeutic Hypothermia in Neonates. Front Pharmacol 2020;11:587. [PMID: 32477113 DOI: 10.3389/fphar.2020.00587] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
29 Giaginis C, Theocharis S, Tsantili-Kakoulidou A. Current toxicological aspects on drug and chemical transport and metabolism across the human placental barrier. Expert Opin Drug Metab Toxicol 2012;8:1263-75. [PMID: 22780574 DOI: 10.1517/17425255.2012.699041] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 3.2] [Reference Citation Analysis]
30 Smits A, Annaert P, Allegaert K. Drug disposition and clinical practice in neonates: Cross talk between developmental physiology and pharmacology. International Journal of Pharmaceutics 2013;452:8-13. [DOI: 10.1016/j.ijpharm.2012.03.035] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
31 Brantley SJ, Argikar AA, Lin YS, Nagar S, Paine MF. Herb-drug interactions: challenges and opportunities for improved predictions. Drug Metab Dispos 2014;42:301-17. [PMID: 24335390 DOI: 10.1124/dmd.113.055236] [Cited by in Crossref: 104] [Cited by in F6Publishing: 64] [Article Influence: 13.0] [Reference Citation Analysis]
32 Krzyszczyk P, Acevedo A, Davidoff EJ, Timmins LM, Marrero-Berrios I, Patel M, White C, Lowe C, Sherba JJ, Hartmanshenn C, O'Neill KM, Balter ML, Fritz ZR, Androulakis IP, Schloss RS, Yarmush ML. The growing role of precision and personalized medicine for cancer treatment. Technology (Singap World Sci) 2018;6:79-100. [PMID: 30713991 DOI: 10.1142/S2339547818300020] [Cited by in Crossref: 58] [Cited by in F6Publishing: 27] [Article Influence: 29.0] [Reference Citation Analysis]
33 Rasool MF, Khalid S, Majeed A, Saeed H, Imran I, Mohany M, Al-Rejaie SS, Alqahtani F. Development and Evaluation of Physiologically Based Pharmacokinetic Drug-Disease Models for Predicting Rifampicin Exposure in Tuberculosis and Cirrhosis Populations. Pharmaceutics 2019;11:E578. [PMID: 31694244 DOI: 10.3390/pharmaceutics11110578] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
34 Stader F, Penny MA, Siccardi M, Marzolini C. A comprehensive framework for physiologically based pharmacokinetic modelling in Matlab®. CPT Pharmacometrics Syst Pharmacol 2019. [PMID: 30779335 DOI: 10.1002/psp4.12399] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
35 Himebauch AS, Zuppa A. Methods for pharmacokinetic analysis in young children. Expert Opinion on Drug Metabolism & Toxicology 2014;10:497-509. [DOI: 10.1517/17425255.2014.885502] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
36 Allegaert K, Fanos V, van den Anker JN, Laër S. Perinatal pharmacology. Biomed Res Int 2014;2014:101620. [PMID: 24822175 DOI: 10.1155/2014/101620] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
37 Hunt CA, Kennedy RC, Kim SH, Ropella GE. Agent-based modeling: a systematic assessment of use cases and requirements for enhancing pharmaceutical research and development productivity. Wiley Interdiscip Rev Syst Biol Med 2013;5:461-80. [PMID: 23737142 DOI: 10.1002/wsbm.1222] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
38 Leeder JS, Brown JT, Soden SE. Individualizing the use of medications in children: making Goldilocks happy. Clin Pharmacol Ther 2014;96:304-6. [PMID: 24926777 DOI: 10.1038/clpt.2014.130] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
39 Bouzom F, Ball K, Perdaems N, Walther B. Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs?: PBPK MODELLING TOOLS. Biopharm Drug Dispos 2012;33:55-71. [DOI: 10.1002/bdd.1767] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 6.1] [Reference Citation Analysis]
40 Pilla Reddy V, Bui K, Scarfe G, Zhou D, Learoyd M. Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations. Clin Pharmacol Ther 2019;105:229-41. [PMID: 29717476 DOI: 10.1002/cpt.1103] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 7.3] [Reference Citation Analysis]
41 Dogra P, Butner JD, Chuang YL, Caserta S, Goel S, Brinker CJ, Cristini V, Wang Z. Mathematical modeling in cancer nanomedicine: a review. Biomed Microdevices 2019;21:40. [PMID: 30949850 DOI: 10.1007/s10544-019-0380-2] [Cited by in Crossref: 55] [Cited by in F6Publishing: 33] [Article Influence: 27.5] [Reference Citation Analysis]
42 Batchelor HK, Marriott JF. Paediatric pharmacokinetics: key considerations. Br J Clin Pharmacol 2015;79:395-404. [PMID: 25855821 DOI: 10.1111/bcp.12267] [Cited by in Crossref: 83] [Cited by in F6Publishing: 53] [Article Influence: 13.8] [Reference Citation Analysis]
43 Djebli N, Fabre D, Boulenc X, Fabre G, Sultan E, Hurbin F. Physiologically Based Pharmacokinetic Modeling for Sequential Metabolism: Effect of CYP2C19 Genetic Polymorphism on Clopidogrel and Clopidogrel Active Metabolite Pharmacokinetics. Drug Metab Dispos 2015;43:510-22. [DOI: 10.1124/dmd.114.062596] [Cited by in Crossref: 32] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
44 Stader F, Wuerthwein G, Groll AH, Vehreschild J, Cornely OA, Hempel G. Physiology-Based Pharmacokinetics of Caspofungin for Adults and Paediatrics. Pharm Res 2015;32:2029-37. [DOI: 10.1007/s11095-014-1595-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
45 Chaphekar N, Caritis S, Venkataramanan R. Model-Informed Dose Optimization in Pregnancy. J Clin Pharmacol 2020;60 Suppl 1:S63-76. [PMID: 33205432 DOI: 10.1002/jcph.1777] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
46 Lu H, Rosenbaum S. Developmental pharmacokinetics in pediatric populations. J Pediatr Pharmacol Ther. 2014;19:262-276. [PMID: 25762871 DOI: 10.5863/1551-6776-19.4.262] [Cited by in Crossref: 34] [Cited by in F6Publishing: 70] [Article Influence: 5.7] [Reference Citation Analysis]